Articles tagged with Hormone Therapy
Researchers have discovered a new treatment option for thyroid cancer that allows patients to continue their thyroid hormone replacement therapy while undergoing radioiodine treatment, reducing unpleasant side effects. This breakthrough could improve the overall quality of life for thyroid cancer patients during treatment.
Researchers found that testosterone therapy significantly improved quality-of-life scores in men with mild Alzheimer's disease. However, the study's results do not warrant routine treatment and require further investigation before clinical decisions can be made.
Research suggests that aldosterone, a hormone involved in blood pressure regulation, may also contribute to strokes. Aldosterone blockers have shown promise in animal models, reversing wall-thickening effects on blood vessels. However, gender differences and optimal treatment strategies remain unclear.
A four-year study found a sharp decline in HRT prescribing after the Million Women Study's publication, whereas an earlier study had little effect. Widespread media coverage is believed to have played a significant role in this change.
Researchers found that risedronate therapy significantly reduced plaque and improved periodontal status in postmenopausal women with osteoporosis. The study also highlighted the link between osteoporosis and periodontal disease, suggesting similar treatment and management may minimize tooth loss.
Researchers found that a 12-minute visit with dogs significantly lowered blood pressure, released less harmful hormones, and reduced anxiety among hospitalized heart failure patients. This study demonstrates the benefits of animal-assisted therapy as an adjunct to medical treatment for these patients.
Researchers found that light exposure triggers a massive surge of corticosterone in mice, playing a key role in physiological changes evoked by light. The study suggests light therapy may have beneficial effects on patients with seasonal affective disorder and other metabolic disorders.
Researchers found associations between PBC and family history of Sjogren's syndrome, urinary tract infection, smoking, nail polish use, and hormone replacement therapy. Never having been pregnant also showed protection from developing the disease.
A study of 1901 women with early-stage breast cancer found that longer tamoxifen treatment periods resulted in improved overall survival, particularly in younger patients. Women aged 50-55 showed significant overall survival improvement after five years of treatment.
A study of 208 women with early or advanced breast cancer found that nearly half forgot their tablets and over a tenth deliberately skipped doses. The research highlights the need for doctors to address patients' concerns about hot flushes and injections, which can affect treatment adherence.
A study of 869 women found that radiation therapy after surgery reduced breast cancer recurrence by almost 100%, with an overall survival rate of 97%. Radiation therapy also did not impact patients' quality of life or long-term survival rates.
A new study found that short-term hormone therapy can significantly improve the outlook for men with early-stage prostate cancer. Researchers discovered that testosterone suppression before and during radiotherapy reduced the risk of relapse by up to 44%.
Men who survive testicular cancer are at higher risk of developing a second cancer for at least 35 years after diagnosis, mostly due to late side effects of treatment. Cancers such as bladder, colon, and stomach cancers account for most excess risks, with young patients facing even greater dangers.
A study of 55,371 postmenopausal women found that estrogen-progestin and estrogen therapies increased breast cancer risk by 29% and 10%, respectively, after five years. The association applied to all ethnic groups except African-Americans.
Recent evidence suggests a link between estrogen deprivation and joint pain, particularly in women undergoing hormone therapy for breast cancer. Studies have shown that aromatase inhibitors and other estrogen-depleting treatments can increase the risk of musculoskeletal symptoms, including joint pain.
A new study by Kishan Pandya and colleagues found that gabapentin significantly reduced hot flash severity scores in women with breast cancer. The results suggest that gabapentin can be added to the list of non-hormonal agents for controlling hot flashes in these patients, with further studies needed on higher doses.
A Yale University study found that early use of hormone therapy is linked to fewer wrinkles and firmer skin. The researchers compared 11 non-users with nine long-term hormone therapy users and found significant decreases in wrinkle severity and rigidity.
Researchers aim to investigate whether starting hormone therapy early can prevent atherosclerosis and heart attacks. The KEEPS trial, led by Yale University, seeks healthy women aged 42-58 for a double-blind study exploring the effects of early menopausal hormone therapy.
Researchers argue that the pharmaceutical industry and medical professionals colluded to promote the view that menopause is a 'deficiency disease' for which women needed long-term treatment. This has led to increased risk of cancer, cardiovascular health issues, and other adverse effects.
A recent study published in The Journal of Clinical Pharmacology found that use of over-the-counter (OTC) topical progesterone results in significant drug exposure through skin absorption, comparable to prescribed oral progesterone products. The study revealed similar rates of adverse effects among women taking both types of progesterone.
A study of 8,405 women found that moderate or severe vasomotor symptoms were reported by 21.2% of former hormone therapy users, compared to 4.8% of placebo group respondents. Lifestyle and medical strategies may help manage symptoms after discontinuing hormone therapy.
Research suggests that hormone replacement therapy (HRT) can be beneficial for women experiencing moderate to severe vasomotor symptoms due to estrogen deficiency. Additionally, studies have shown that HRT does not compromise survival in patients who are survivors from gynecologic cancer.
A recent study by Yale University researchers found that sEGFR, a breast cancer growth regulator, can indicate the effectiveness of letrozole in postmenopausal women with metastatic breast cancer. Decreased concentrations of sEGFR were seen in 73% and 76% of patients after one month and three months of treatment respectively.
A cross-sectional study of 2,162 men found that 38.7% had low testosterone levels and 23% had a history of diabetes. Men with diabetes and low T were 2.09 times more likely to have hypogonadism, a condition characterized by low testosterone production.
Tercica has presented human and animal safety data showing no immunotoxic effects with long-term rhIGF-1 treatment. The data also demonstrate a reduction in the incidence of some endocrine cancers in animals, providing further evidence supporting the long-term safety of rhIGF-1 therapy.
A new dosing approach for growth hormone based on serum levels of insulin-like growth factor-I (IGF-I) shows improved height increases in children with growth hormone deficiency or short stature. The study found that increasing IGF-I levels resulted in significant gains in height, particularly in those receiving higher doses.
Researchers found that the drop in estrogen levels during menopause is linked to increased cortisol levels and abdominal fat. Estrogen replacement therapy may help prevent this rise in cortisol and delay or prevent weight issues.
A recent study analyzed 10 studies on HRT and breast cancer, finding that randomized controlled trials show an increased risk of recurrence. The authors conclude that qualitative studies are unreliable due to methodological limitations and potential publication bias.
A new mathematical model simulates 10-year disease-free survival in postmenopausal women with hormone-receptor positive breast cancer. The model reveals that the best treatment strategy depends on tumor biology, recommending tamoxifen and aromatase inhibitor treatment for different cases.
A study published in Nature Neuroscience found changes in GABAA receptors linked to seizures and anxiety during the menstrual cycle. The researchers suggest that these changes may be relevant to post-partum depression and mood swings during pregnancy, and could provide novel therapeutic targets for PMS and catamenial epilepsy.
A large collaborative analysis of early breast cancer trials found that standard treatments such as chemotherapy and hormonal therapy can halve the 15-year risk of death from breast cancer. The study included data from 145,000 women with early breast cancer in 194 randomised trials.
A new study found no association between hormonal contraceptive use and changes in CD4+ cell count or viral load suppression after initiating HAART. Continuous HAART use significantly improved HIV disease progression outcomes, with increased CD4+ counts and undetectable viral loads.
A study found that commercially available extracts of black cohosh increased cell killing by two of four drugs used in cancer therapy for breast cancer patients. However, the herb also decreased the effectiveness of one drug. Further research is needed to understand why these effects occur.
A non-surgical method called mesotherapy claims to remove fat and contour the body, but there is no scientific evidence supporting its safety or efficacy. Plastic surgeons recommend liposuction instead due to its proven track record of safely removing fat.
A new study found that erythropoietin reduced inflammation and cell death, improving functional recovery after hemorrhagic stroke in rats. The treatment also showed decreases in brain water content and increases in behavioral recovery.
Two trials found that menopausal hormone therapy may increase breast cancer recurrence risk, but a new trial suggests no association. Researchers call for further study on safe treatment regimens.
A state-of-the-science panel urges caution in treating menopausal symptoms with hormones due to risks and limited evidence. Non-hormonal treatment approaches are recommended for further research.
Researchers found that vaccinating mice with prostate cancer immediately after hormone therapy triggers a stronger T-cell response against the cancer. The strategy could lead to better vaccine effectiveness in humans, delaying the need for additional treatments or hormone therapy.
A one-year study found growth hormone treatment significantly reduced intra-abdominal fat and improved insulin sensitivity in postmenopausal women with abdominal adiposity. The treatment also increased thigh muscle area and lowered LDL cholesterol concentration.
A recent study found that vitamin D injections can reduce mortality rates by up to 20% in dialysis patients. Currently, only half of kidney failure patients receive this treatment, highlighting the need for more aggressive treatment strategies.
Research found that hormone therapy for prostate cancer can lead to temporary declines in visual memory and recognition speed. However, cognitive function appears to be well preserved despite these changes.
A large clinical trial found that menopausal hormone therapy increased the incidence of urinary incontinence, particularly stress UI, and worsened its characteristics among symptomatic women. The study suggests that MHT should be reevaluated as a treatment option for UI.
The study found no benefit for women's health-related quality of life from post-menopausal hormone therapy, but increased risk of breast cancer, cardiovascular events, and stroke. This has led to a dilemma among stakeholders, including physicians and pharmaceutical companies.
Researchers at Medical College of Georgia have found changes in blood vessel chemistry that may explain how estrogen increases the risk of heart disease in older women. Estrogen targets nitric oxide synthase, producing a powerful age-promoting oxygen-free radical instead of making nitric oxide.
Researchers examine the 75-year history of hormone therapy, including the Women's Health Initiative study that found increased risks of breast cancer, dementia, and heart attacks in women taking combination hormone therapy. The authors argue that conflicting interests between women, physicians, and drug companies have contributed to th...
Researchers at the University at Buffalo are conducting a 12-week study to evaluate the effectiveness of an amino acid supplement in reducing hot flashes in postmenopausal women. The trial will compare the active treatment with a placebo, and results may offer an alternative to hormone replacement therapy.
Researchers discovered that certain mutations in the androgen receptor cause advanced prostate cancer when introduced into healthy mice. These findings shed light on why hormone withdrawal therapy fails to cure most men with advanced prostate cancer, and open the door to discovering new, effective therapies.
A new study shows that exercise improves three measures of heart protection in postmenopausal women, including better blood clotting profiles and reduced blood clot activation. Regular physical activity may help prevent the formation of blood clots, leading to a lower risk of heart attacks.
A study found that women taking SSRIs with CYP2D6 variant alleles had lower tamoxifen metabolite levels, potentially impacting treatment efficacy. The authors suggest testing CYP2D6 genetic variants to personalize tamoxifen therapy.
A study found that prostate cancer patients receiving androgen deprivation therapy were at high risk of osteoporosis, yet few received prevention or treatment. Only primary care physicians were aggressive in managing osteoporosis risk.
A study presented at the SABCS showed a 30 percent reduction in breast cancer recurrence when postmenopausal women with hormone-receptor-positive breast cancer were switched from tamoxifen to AROMASIN after 2-3 years. This finding supports ASCO recommendations for adjuvant therapy with aromatase inhibitors.
The ATAC study's 5-year follow-up results show anastrozole increased disease-free survival and reduced cancer recurrence, with fewer side effects compared to tamoxifen. Anastrozole is now considered the preferred initial adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer.
A new study by Loyola Medicine found that tamoxifen or other hormonal therapy alone may not be sufficient to treat hormone-dependent breast cancer. Chemotherapy proved more effective in stopping cancer recurrence, especially when combined with tamoxifen.
The use of celebrities to market drugs and diseases is a practice that raises concerns about public health and transparency. According to investigative reporter Ray Moynihan, this practice can lead to a lack of balance in the public debate about major health problems, as well as a failure to disclose potential conflicts of interest.
A four-year project aims to understand how androgen influences the skeleton, with potential implications for stress fracture prevention and treating osteoporosis. The study examines the effects of androgen therapy on bone health in both men and women.
A randomized, double-blind, placebo-controlled trial found that DHEA replacement therapy significantly decreases both visceral and subcutaneous abdominal fat in elderly men and women. The therapy also improves insulin action, correlating with the reduction in visceral fat.
Researchers examine how and why hormone therapy affects cognition, finding that treatment regimen influences memory performance. Continuous versus cyclical estrogen regimens show differing effects on cognitive function, with cyclical regimens leading to more errors in reference and working memory tests.
A study found that word retention drops sharply after two minutes among men undergoing testosterone deprivation therapy, despite initial encoding being similar to healthy men. The lack of testosterone affects the function of the hippocampus, a curved ridge in the brain controlling learning and memory.
Research suggests that teenage hormone therapy to reduce adult height in tall girls is linked to impaired fertility later in life. Women who received oestrogen therapy were more likely to experience difficulty becoming pregnant and had a lower per cycle rate of conception.
A new Group Health study examines the link between hormone therapy (HT) and breast density in women of various categories. The study found that estrogen-only therapy increases breast density, while progesterone use does not; longer HT use and older age at first use also increase breast density.